3 days popular7 days popular1 month popular3 months popular

Treating Triple-Negative Breast Cancer With Vegetable-Derived Compound

A new compound created from a rich source in vegetables including broccoli and brussel sprouts has been developed to combat triple-negative breast (TNBC). This research was presented at the 2012 (AAPS) Annual Meeting and Exposition, the world’s largest pharmaceutical sciences meeting, in Chicago, Ill., during .

TNBC accounts for approximately 15-20 percent of all cases in the U.S. It is one of the most aggressive forms of ; it grows faster, spreads to other parts of the body earlier, is harder to detect on a mammogram and recurs more often.

Mandip Sachdeva, Ph.D. and Chandraiah Godugu, P.h.D. from Florida A&M University, in collaboration with Stephen Safe, Ph.D., from Texas A&M University, have evaluated the activity of novel C-substituted diindolylmethane (C-DIM) derivatives and demonstrated that they have superior anticancer activities. Sachdeva’s study reveals that these synthetic derived from diindolylmethane (DIM), commonly found in various types of , can be used to treat several types of cancer, including triple-negative breast cancer. C-DIMs are also being investigated for their cancer prevention activity.

“Targeted treatment options for TNBC are limited; current treatments, such as infusions, result in poor patient compliance and increased toxicity,” said Sachdeva. “We are confident that the compounds we are currently working with are an effective treatment for triple-negative breast cancer. These compounds are safer for the patient than current treatments available.”

In contrast to existing anticancer drugs, the diindolylmethane compounds are orally active, so they could be available to patients in pill form and safe to take daily. When taken in combination with existing anticancer drugs, the diindolylmethane compounds can effectively decrease the number of treatments a patient receives.

Source

This work was supported by DOD grant number W81XWH-11-1-0211 and NIMHD P20 grant, 1P20MD006738-01.
American Association of Pharmaceutical Scientists